Dr Reddy’s Laboratories anticipates a gradual recovery this fiscal year. The company faced a profit drop last year due to US business pressures. However, operations in India, Europe, and emerging markets show healthy growth. New launches like Semaglutide and Abatacept are expected to drive future expansion. Margins are set to improve with better product mix and cost controls.
Titan Q1 update: Business grows 41% as jewellery, watches sales gain pace
Titan’s consumer sector experienced a remarkable forty-one percent surge in the first quarter, driven by robust festival demand that significantly elevated sales in its jewellery
July 6, 2026